Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Research & Development (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Research & Development for 7 consecutive years, with $15.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 59.83% to $15.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $109.2 million, a 35.53% decrease, with the full-year FY2025 number at $109.2 million, down 35.53% from a year prior.
  • Research & Development was $15.6 million for Q4 2025 at Pliant Therapeutics, down from $17.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $47.8 million in Q3 2024 to a low of $15.6 million in Q4 2025.
  • A 5-year average of $29.0 million and a median of $27.8 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 47.67% in 2024, then crashed 62.44% in 2025.
  • Pliant Therapeutics' Research & Development stood at $18.8 million in 2021, then skyrocketed by 33.93% to $25.1 million in 2022, then soared by 32.13% to $33.2 million in 2023, then increased by 16.91% to $38.8 million in 2024, then plummeted by 59.83% to $15.6 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Research & Development are $15.6 million (Q4 2025), $17.9 million (Q3 2025), and $32.2 million (Q2 2025).